Although both mAbs induced a significant inhibition in the proliferation of the primary USPC cell lines tested, regardless of their high or low HER-2/neu expression, pertuzumab was consistently found to be more effective than trastuzumab in inhibiting tumour proliferation. Here, ERBB2 is linked to neoplasm.